Evaluating perceptions of Ofatumumab in Multiple Sclerosis via Social Media Listening – Early 6 months post approval data

Author(s): M. Williams¹, J. Robinson², B. Luscher², K. Elliott -Maksymowicz², J. Kerley², Chinmay Deshpande³

¹Jio Life Wellness Group, Smyrna, United States; ²Real Chemistry, Philadelphia, United States; ³Novartis Pharmaceuticals Corporation, East Hanover, United States

Introduction

Ofatumumab (Kesimpta), a fully human anti-CD20 monoclonal antibody (mAb) and B-cell therapy demonstrated positive efficacy and safety results in Phase III ASCLEPIOS I and II studies. Based on these results, Kesimpta was approved by the US FDA in August 2020 for relapsing MS.

Objective

The objective was to understand the perceptions and sentiments of stakeholders (patients, healthcare providers [HCPs], payers, advocacy groups) for Kesimpta, in the US in 6 months of its availability in the real-world as a treatment for MS.

Methods

• This was a social media listening study conducted through open social media platforms such as Twitter, blogs, forums, Facebook, and Instagram.

• Search analysis was undertaken using Google.

• Representative keyword samples are captured to reflect the overall landscape, and this is used to search the search media landscapes.

• Search technology that visualises the complete matrix of top search volumes. The search analysis and data selection.

• It then assigns volume and visibility recommendations. Relevant, specific insights and recommendations are shared.

• Topical clusters based on shared sentiments of stakeholders, and our team of in-house analysts searched the area of interest.

Advantages to Kesimpta

• Major themes viewed as advantages to Kesimpta across all stakeholders were route of administration, efficacy, and safety profile (Figure 3).

• Individuals commented positively about Kesimpta’s self-administered treatment route. Patients indicated that self-injection ‘can be administered anywhere’ and ‘lowers risk of contracting COVID at infusion center’.

• Kesimpta was further noted for having 95% to 98% efficacy in preventing lesions, and was regarded as ‘leading DMT’ across Ocrevus.

Overall perception of the stakeholders

• Kesimpta was perceived to be superior to competitor injectables. Tysabri, Ocrevus, Lemtrada, & Kesimpta were all perceived to be high efficacy DMDs, often referenced as more ‘aggressive’ options (Figure 4). Kesimpta was perceived to be much safer than Ocrevus and other infusions on the market. The positive sentiment noted ‘how mild’ or ‘non-existent’ were their reactions to Kesimpta and was called “Pandemic-friendly”.

Results

• Overall, 184,505 MS-related posts were identified through social media. Through systematic analysis, 6,895 posts were identified which were authored by stakeholders (i.e. patients & caregivers, HCPs, and advocacy groups) of which 1,036 posts were Kesimpta specific. The flow diagram for identification process is summarised in Figure 2.

• Overall perception of the stakeholders

Drivers of adoption/switching to Kesimpta

• The most common reasons for adoption of Kesimpta were patients was efficacy/reduced relapse and lesion activity, flexibility/convenience and at home administration, perceived lack of side effects/favorable safety profile and easy injection process (Figure 5). HCPs considered switching patients to Kesimpta due to efficacy and at-home administration. Advocacy groups largely echoed the dialogue of both HCPs and patients.

Conclusions

• For overall perception, Kesimpta had the most positive sentiment among all injectable DMTs driven by tolerability, efficacy and convenience.

• Advantages for Kesimpta across stakeholders: patients, HCPs and advocacy were route of administration, efficacy and safety.

• The most common reasons for switching to Kesimpta was flexibility/convenience and at home administration, efficacy/reduced relapse and lesion activity, perceived lack of side effects/favorable safety profile and easy injection process.

Disclosures


Acknowledgements

Authors would thank Mrs. Surabhi Aggarwal (Novartis healthcare pvt ltd, India) for writing support and Moganti Ravi Sankar (Novartis healthcare pvt ltd, India) for designing the poster layout.

Poster presented at 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Vienna, Austria, 13-15 October 2021. This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.